Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2005
12/01/2005US20050267183 Selective estrogen receptor modulators
12/01/2005US20050267168 Pentanoic acid derivatives
12/01/2005US20050267167 Pentanoic acid derivatives
12/01/2005US20050267152 Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/01/2005US20050267137 Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof
12/01/2005US20050267133 Pyrazolopyrimidines as kinase inhibitors
12/01/2005US20050267129 Dipeptide nitrile cathepsin K inhibitors
12/01/2005US20050267123 6-Membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
12/01/2005US20050267114 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
12/01/2005US20050267064 Containing unmethylated CpG dinucleotides, and an allergen; desensitization
12/01/2005US20050267062 Endothelial growth factors; antiischemic agents; neovascularization
12/01/2005US20050267057 Redirect a Th2 response to a Th1 response; treating asthma, allergies, infections, cancer immunotherapy; contain unmethylated cytosine-guanine (CpG) dinucleotides
12/01/2005US20050267048 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae
12/01/2005US20050267044 Novel compounds and compositions as cathepsin S inhibitors
12/01/2005US20050267038 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
12/01/2005US20050267022 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
12/01/2005US20050267016 Therapeutic oligopeptide for treatment of tumor disorders; contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle
12/01/2005US20050267014 Pharmaceutical composition comprising factor VII polypeptides and tranexamic acid
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer
12/01/2005US20050266060 Transdermal delivery system for treatment of cognitive disorders
12/01/2005US20050265969 Therapeutic chemokine receptor antagonists
12/01/2005US20050265965 Modified cytokines for use in cancer therapy
12/01/2005US20050265932 Collagenolytic active enzyme containing compositions, and their use in the dental field
12/01/2005CA2567704A1 Selective serotonin receptor inverse agonists as therapeutics for disease
12/01/2005CA2508585A1 Transdermal delivery system for treatment of cognitive disorders
11/2005
11/30/2005EP1600506A2 Oligoribonucleotides and ribonucleases for cleaving RNA
11/30/2005EP1600505A1 Escherichia coli phytase
11/30/2005EP1600458A1 Novel gene relating to fibrotic conditions
11/30/2005EP1600457A1 Peptide derivatives having beta-secretase inhibitory activity
11/30/2005EP1600445A1 Medicinal composition
11/30/2005EP1600442A1 Heteroarylcarbamoylbenzene derivative
11/30/2005EP1600440A1 Indole derivative compounds and drugs containing the compounds as the active ingredient
11/30/2005EP1600180A2 Antiproliferative drug and delivery device
11/30/2005EP1600170A1 Sustained-release pharmaceutical composition for lung administration
11/30/2005EP1600166A1 Skeletal muscle protecting agent
11/30/2005EP1600165A1 Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent
11/30/2005EP1600163A1 Use of the neurotoxic component of botulinum toxins for the treatment of spastic muscle
11/30/2005EP1600160A1 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
11/30/2005EP1600159A1 A method for synthesizing different Zolpidem hemitartrate derivatives
11/30/2005EP1600157A1 Enteric sustained-release fine particles for tamsulosin or its salt and process for producing the same
11/30/2005EP1600152A1 Use of LIF in cosmetics and dermatology
11/30/2005EP1600141A1 Collagenolytic active enzyme containing compositions, and their use in the dental field
11/30/2005EP1599482A1 Pyrazolo 1,5-a pyrimidine derivatives
11/30/2005EP1551431A4 Purified amylase inhibitor and novel process for obtaining the same
11/30/2005EP1467996B1 Pyrimidotriazines as phosphatase inhibitors
11/30/2005EP1430131B1 Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
11/30/2005EP1401839B9 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta [a] naphthalene
11/30/2005EP1392702B1 Compounds and methods for inhibiting mrp1
11/30/2005EP1317483B1 Variants of allergenic proteins of the group 2 of dermatophagoides
11/30/2005EP1313740B1 Prodrugs of imidazopyridine derivatives
11/30/2005EP1313697B1 Immunoregulatory compounds, derivatives thereof and their use
11/30/2005EP1289537B1 Method of treating chronic ulcers
11/30/2005EP1287005B1 Benzoic acid esters having antiplasmid effect
11/30/2005EP1282439B1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR
11/30/2005EP1257299B9 Radioactive therapeutic liposomes
11/30/2005EP1221941A4 Powder pharmaceutical formulations
11/30/2005EP1194436B1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
11/30/2005EP1173418B1 Crystalline form 3 of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide
11/30/2005EP1159278B1 Inhibitors of aspartyl protease
11/30/2005EP1140786B1 Reductive alkylation of secondary amines with hydrosilane
11/30/2005EP1115428B1 Cationic dendrimeric compounds and their use as oligonucleotide/polynucleotide carriers
11/30/2005EP1091943B1 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
11/30/2005EP1079832B1 Use of vitamin pp compounds
11/30/2005EP1071474B1 Substituted porphyrins
11/30/2005EP0925291B1 Spirocyclic dopamine receptor subtype ligands
11/30/2005EP0891377B1 Inhibitor and stimulator of haematopoietic stem cell proliferation and uses thereof
11/30/2005EP0888341B1 Novel sulphur derivatives comprising an amide bond, method for preparing same, use thereof as drugs, and pharmaceutical compositions containing such derivatives
11/30/2005CN1703425A Crystallization of IGF-1
11/30/2005CN1703420A Promoters exhibiting endothelial cell specificity and methods of using same
11/30/2005CN1703410A Isoquinoline compounds and medicinal use thereof
11/30/2005CN1703405A Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors
11/30/2005CN1703403A Metabotropic glutamate receptor antagonists
11/30/2005CN1703401A Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/30/2005CN1703395A Aryl and heteroaryl compounds and methods to modulate coagulation
11/30/2005CN1703393A Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
11/30/2005CN1703234A The use of low-molecular-weight thrombin inhibitor
11/30/2005CN1703226A Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
11/30/2005CN1703218A Combinations of benzodithiazoles and COx-2 inhibitors for the treatment of pain
11/30/2005CN1703214A Amino acid compositions for improving central functions
11/30/2005CN1703207A Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta
11/30/2005CN1703206A Plaster for the treatment of dysfunctions and disorders of nail growth
11/30/2005CN1701792A Preparation for external use on skin
11/30/2005CN1701791A Medicine for treating allergic skin disease and its preparation process
11/30/2005CN1229502C Fermentative preparation process for cytostatics and crystal form thereof
11/30/2005CN1229499C Phosphodiesterase 8A
11/30/2005CN1229385C Composition for stimulating megacaryocyte growth and differentiation and process thereof
11/30/2005CN1229377C Spiro [Piperidine-4,1'-pyrrolo[3,4-c] pyrrole]
11/30/2005CN1229374C Substituted bisindolylmaleimides for inhibition of cell proliferation
11/30/2005CN1229373C Piperidinee derivatives as neurokinin1 antagonists
11/30/2005CN1229371C Benzopyranyl guanidine derivtives, process for preparation thereof and pharmaceutical compositions containing them
11/30/2005CN1229370C Novel derivatives of flavones, xanthones and coumarins
11/30/2005CN1229353C Method and compositions utilizing quinazolinones
11/30/2005CN1229349C Pyridine-3-carboxylic acid derivative
11/30/2005CN1229347C Process for production of piperidine derivative fexofenadine
11/30/2005CN1229344C Farnesyl transferase inhibitors
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229339C Compounds inhibiting angiogenesis and tumor growth, pharmaceutical preparation containing same and pharmaceutical use thereof
11/30/2005CN1229335C Nervinolin derivatives
1 ... 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 ... 1564